Skip to main content

Table 4 The variables in the univariate analysis for the BCLC-B stage

From: A simple CD4+ T cells to FIB-4 ratio for evaluating prognosis of BCLC-B hepatocellular carcinoma: a retrospective cohort study

Variables

All included patients (n = 1464)

Relative risk (95% CI)

P

Age (years)

1.010 (0.982–1.039)

0.488

Male

0.534 (0.261–1.091)

0.085

BMI (kg/m2)

1.036 (0.890–1.206)

0.649

Child-Pugh score

1.177 (0.858–1.615)

0.312

WBC (109/L)

0.939 (0.791–1.115)

0.472

sCr (μmol/L)

0.997 (0.980–1.015)

0.754

Alb (g/L)

1.023 (0.971–1.077)

0.402

PT (s)

0.953 (0.843–1.078)

0.444

TB (μmol/L) >2ULN

1.954 (0.858–4.451)

0.111

HB (g/dl) <100 g/L

1.229 (0.411–3.669)

0.712

ALT (u/L) ≤49

0.398 (0.212–0.748)

0.004

AST (u/L) >67

2.246 (1.213–4.160)

0.010

Plt (109/L) ≤114

0.389 (0.207–0.732)

0.003

Serum AFP (ng/mL) > 400

1.291 (0.649–2.568)

0.467

Number of tumor ≥2

1.071 (0.563–2.034)

0.835

Maximum tumor diameter (mm) >80

0.816 (0.438–1.521)

0.523

HIV

0.877 (0.434–1.772)

0.715

CD3+ T cells (/μL)

0.999 (0.998–1.000)

0.134

CD4+ T cells (/μL) ≤449

0.326 (0.174–0.611)

<0.001

CD8+ T cells (/μL)

0.998 (0.997–1.000)

0.084

CD4+/CD8+

0.676 (0.403–1.135)

0.138

APRI >1.22

2.872 (1.537–5.366)

0.001

FIB-4 > 5.39

3.404 (1.697–6.829)

0.001

CD4/APRI ≤619.97

0.108 (0.420–0.278)

<0.001

CD4/FIB-4 ≤ 145.93

0.203 (0.103–0.399)

<0.001

  1. BMI Body mass index, HBsAg Hepatitis B surface antigen, TB Total bilirubin, AFP Alpha-fetoprotein, PT Prothrombin time, WBC White blood cell, sCr Serum creatinine, HB Hemoglobin, Plt Platelet, Alb Albumin